Abou Assi, L.; Alkhansa, S.; Njeim, R.; Ismail, J.; Madi, M.; Ghadieh, H.E.; Al Moussawi, S.; Azar, T.S.; Ayoub, M.; Azar, W.S.;
et al. Uncovering the Therapeutic Potential of Lithium Chloride in Type 2 Diabetic Cardiomyopathy: Targeting Tau Hyperphosphorylation and TGF-β Signaling via GSK-3β Inhibition. Pharmaceutics 2024, 16, 955.
https://doi.org/10.3390/pharmaceutics16070955
AMA Style
Abou Assi L, Alkhansa S, Njeim R, Ismail J, Madi M, Ghadieh HE, Al Moussawi S, Azar TS, Ayoub M, Azar WS,
et al. Uncovering the Therapeutic Potential of Lithium Chloride in Type 2 Diabetic Cardiomyopathy: Targeting Tau Hyperphosphorylation and TGF-β Signaling via GSK-3β Inhibition. Pharmaceutics. 2024; 16(7):955.
https://doi.org/10.3390/pharmaceutics16070955
Chicago/Turabian Style
Abou Assi, Layal, Sahar Alkhansa, Rachel Njeim, Jaafar Ismail, Mikel Madi, Hilda E. Ghadieh, Sarah Al Moussawi, Tanya S. Azar, Maurice Ayoub, William S. Azar,
and et al. 2024. "Uncovering the Therapeutic Potential of Lithium Chloride in Type 2 Diabetic Cardiomyopathy: Targeting Tau Hyperphosphorylation and TGF-β Signaling via GSK-3β Inhibition" Pharmaceutics 16, no. 7: 955.
https://doi.org/10.3390/pharmaceutics16070955
APA Style
Abou Assi, L., Alkhansa, S., Njeim, R., Ismail, J., Madi, M., Ghadieh, H. E., Al Moussawi, S., Azar, T. S., Ayoub, M., Azar, W. S., Hamade, S., Nawfal, R., Haddad, N.-R., Harb, F., Faour, W., Khalil, M. I., & Eid, A. A.
(2024). Uncovering the Therapeutic Potential of Lithium Chloride in Type 2 Diabetic Cardiomyopathy: Targeting Tau Hyperphosphorylation and TGF-β Signaling via GSK-3β Inhibition. Pharmaceutics, 16(7), 955.
https://doi.org/10.3390/pharmaceutics16070955
